Clinical Trial: Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.

U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07679412) titled 'Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.' on June 25.

Brief Summary: The goal of this exploratory clinical study is to evaluate the safety and efficacy of Cytomegalovirus-Specific T cells (LB-DTK-CMV) to treat patients diagnosed with antiviral-resistant and refractory cytomegalovirus retinitis. The main questions it aims to answer are:

* What adverse events occur after the infusion of LB-DTK-CMV?

* What is the duration of efficacy following treatment?

* Is there a clinically significant reduction in CMV viral load in plasma and aqueous...